You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Indirect comparison of pembrolizumab plus chemotherapy vs. atezolizumab plus chemotherapy for advanced squamous non-small-cell lung cancer

From: Which is the optimal immunotherapy for advanced squamous non-small-cell lung cancer in combination with chemotherapy: anti-PD-1 or anti-PD-L1?

Item Statistical analysis
HR / RRa (95%CI) P-value
Overall
 OS 0.67 0.47 0.94 0.02
 PFS 0.79 0.60 1.04 0.10
Overall
 ORR 1.26 0.93 1.72 0.14
 All cause AE 0.98 0.95 1.01 0.25
 Grade 3–5 AE 0.87 0.76 1.01 0.06
PD-L1 Highb
 OS 1.09 0.52 2.28 0.82
 PFS 1.55 0.84 2.84 0.16
PD-L1 Lowc
 OS 0.43 0.24 0.76 < 0.01
 PFS 0.80 0.51 1.26 0.33
PD-L1 Negatived
 OS 0.74 0.40 1.38 0.35
 PFS 0.46 0.28 0.75 < 0.01
  1. Abbreviations: CI confidence interval, HR Hazard ratio, RR Risk ratio, OS overall survival, PFS progression-free survival, ORR objective response rate, AE adverse event, PD-L1 programmed death ligand 1. A statistical test with P-value ≤ 0.05 was considered as significant
  2. In IMpower131, PD-L1 expression was scored by immunohistochemistry (SP142 assay) in tumor cells (as percentage of PD-L1-expressing tumor cells ≥50%, TC3; ≥5% and < 50%, TC2; ≥1% and < 5%, TC1 and < 1%, TC0) and tumor-infi ltrating immune cells (as percentage of tumor area:≥10%, IC3; ≥5% and < 10%, IC2; ≥1% and < 5%, IC1; and < 1%, IC0). In KEYNOTE-407, PD-L1 expression was scored by immunohistochemistry (22C3 assay) in tumor cells (as percentage of PD-L1-expressing tumor cells TPS ≥50%, ≥1% and <50%, and < 1%)
  3. aHR is used for OS and PFS evaluation, RR is used for ORR and AE evaluation
  4. bPD-L1 High is defined as TC3 or IC3 in IMpower131, TPS ≥50% in KEYNOTE-407
  5. cPD-L1 Low is defined as TC1/2 or IC1/2 in IMpower131, TPS ≥1% and < 50% in KEYNOTE-407
  6. dPD-L1 Negative is defined as TC0 and IC0 in IMpower131, TPS < 1% in KEYNOTE-407